SavedAdd your journal

Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2026 / Volume: 44 Issue: 1

Potential Drug-Drug Interactions in Pediatric Patients of a Teaching Hospital In Northern Cyprus: A Retrospective Study

Rım Dırı(NEAR EAST UNIVERSITY, FACULTY OF PHARMACY)0009-0005-2857-1694
Meryem Deniz Aydın(NEAR EAST UNIVERSITY, FACULTY OF PHARMACY)0009-0006-2142-9975
Abdikarim Mohamed Abdi(YEDITEPE UNIVERSITY, FACULTY OF PHARMACY)0000-0002-5064-7094
Pages
—
Publication Date
2024-03-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Utilizing multiple databases to enhance pDDI identification and prevention is also crucial.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hospitalized infants and children are exposed to various medications, leading to potential drug-drug interactions (pDDIs).
📊
Key Findings & Data:All charts of pediatric patients hospitalized between September 1st, 2017, and August 30, 2018, were reviewed.
💡
Conclusion & Impact:Utilizing multiple databases to enhance pDDI identification and prevention is also crucial.
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:drug interactions · pediatrics · drug safety

Abstract

Hospitalized infants and children are exposed to various medications, leading to potential drug-drug interactions (pDDIs). A retrospective observational study was conducted in a Northern Cyprus tertiary hospital to determine the frequency, types, and associated factors of pDDIs in hospitalized pediatric patients. All charts of pediatric patients hospitalized between September 1st, 2017, and August 30, 2018, were reviewed. Medications used concomitantly during hospitalization were screened for pDDIs using three DDI databases; Lexicomp TM 3.0.2, drugs.com, and Medscape. Of the 332 patients examined, 230 (69.2%) patient files met the inclusion criteria. The prevalence rates of pDDIs were 27.8%, 24.8%, and 23%, according to Lexicomp, Drugs.com, and Medscape databases, respectively. Young children (aged 2-6) had the highest percentage of pDDIs with a significant difference between databases (P < 0.05).Patients with pDDIs had longer hospital stays and were on more medications than those without (P < 0.05). Our study revealed that moderate severity pDDIs were common, and there were significant variations between databases. While severe pDDIs are rare, they may be life threatening. Collaborative efforts involving pediatricians and clinical pharmacists are necessary to address pDDIs in pediatric medication management. Utilizing multiple databases to enhance pDDI identification and prevention is also crucial.

Özet

Hospitalized infants and children are exposed to various medications, leading to potential drug-drug interactions (pDDIs). A retrospective observational study was conducted in a Northern Cyprus tertiary hospital to determine the frequency, types, and associated factors of pDDIs in hospitalized pediatric patients. All charts of pediatric patients hospitalized between September 1st, 2017, and August 30, 2018, were reviewed. Medications used concomitantly during hospitalization were screened for pDDIs using three DDI databases; Lexicomp TM 3.0.2, drugs.com, and Medscape. Of the 332 patients examined, 230 (69.2%) patient files met the inclusion criteria. The prevalence rates of pDDIs were 27.8%, 24.8%, and 23%, according to Lexicomp, Drugs.com, and Medscape databases, respectively. Young children (aged 2-6) had the highest percentage of pDDIs with a significant difference between databases (P < 0.05).Patients with pDDIs had longer hospital stays and were on more medications than those without (P < 0.05). Our study revealed that moderate severity pDDIs were common, and there were significant variations between databases. While severe pDDIs are rare, they may be life threatening. Collaborative efforts involving pediatricians and clinical pharmacists are necessary to address pDDIs in pediatric medication management. Utilizing multiple databases to enhance pDDI identification and prevention is also crucial.

🔖

Cite This Article

Dırı, R., Aydın, M. D., Abdi, A. M. (2024). Potential Drug-Drug Interactions in Pediatric Patients of a Teaching Hospital In Northern Cyprus: A Retrospective Study. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Volume: 44 Issue: 1. https://doi.org/10.52794/hujpharm.1265185

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (22)

  1. Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010;2(3):326-31. https://doi.org/10.4103/0975-1483.66807
  2. Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104(3 Pt 2):585-90.
  3. Pirmohamed M. Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wien Klin Wochenschr. 2010;122(3-4):62-4. https://doi.org/10.1007/s00508-010-1309-1
  4. Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med. 2012;166(1):9-16. https://doi.org/10.1001/archpediatrics.2011.161
  5. Langerová P, Prokes M, Konvalinka M, Furstová J, Urbánek K. Incidence of potential drug interactions in medication prescriptions for children and adolescents in the University Hospital Olomouc, Czech Republic. Eur J Pediatr. 2013;172(5):631-8. https://doi.org/10.1007/s00431-013-1933-7
  6. Yeh ML, Chang YJ, Yeh SJ, et al. Potential drug-drug interactions in pediatric outpatient prescriptions for newborns and infants. Comput Methods Programs Biomed. 2014;113(1):15-22. https://doi.org/10.1016/j.cmpb.2013.07.016
  7. Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children’s Hospitals.Pediatr Crit Care Med. 2016;17(5):e218-28. https://doi.org/10.1097/PCC.0000000000000684
  8. Gonzalez D, Sinha J. Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations. J Clin Pharmacol. 2021;61 Suppl 1(Suppl 1):S175-S187. https://doi.org/10.1002/jcph.1881
  9. Salerno SN, Burckart GJ, Huang SM, Gonzalez D. Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities. Clin Pharmacol Ther. 2019;105(5):1067-1070. https://doi.org/10.1002/cpt.1234
  10. Horace AE, Ahmed F. Polypharmacy in pediatric patients and opportunities for pharmacists’ involvement. Integr Pharm Res Pract. 2015;4:113-126. https://doi.org/10.2147/IPRP.S64535
  11. Baniasadi S, Farzanegan B and Alehashem M. Important drug classes associated with potential drug–drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Ann Intensive Care. 2015;5(44). https://doi.org/10.1186/s13613-015-0086-4
  12. Getachew H, Assen M, Dula F, BhagavathulaAS. Potential drug–drug interactions in pediatric wards of Gondar University Hospital, Ethiopia: A cross sectional study. Asian Pacific Journal of Tropical Biomedicine. 2016;6(6):534-8. https://doi.org/10.1016/j.apjtb.2016.04.002
  13. Bebitoğlu BT, Oğuz E, Nuhoğlu Ç, Dalkılıç AEK, Çirtlik P, Temel F, Hodzic A. Evaluation of potential drug-drug interactions in a pediatric population. Turk Pediatri Ars. 2020;9;55(1):30-38. https://doi.org/10.14744/TurkPediatriArs.2019.60938
  14. Medina-Barajas F, Vázquez-Méndez E, Pérez-Guerrero EE, Sánchez-López VA, Hernández-Cañaveral II, Gabriel A RO, Huerta-Olvera SG. Pilot study: Evaluation of potential drugdrug interactions in hospitalized pediatric patients. Pediatr Neonatol. 2020;61(3):279-289. https://doi.org/10.1016/j.pedneo.2019.11.006
  15. Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan TM. Prevalence, types and predictors of potential drug-drug interactions in pulmonology ward of a tertiary care hospital. Afr J Pharm Pharmacol. 2011;5(10):1303-9. https://doi.org/10.5897/AJPP11.408
  16. Hassanzad M, Tashayoie NS, Mahboobipour AA, Salem F., Baniasadi S. Potential drug-drug interactions in hospitalized pediatric patients with respiratory disorders: A retrospective review of clinically important interactions. Drug Metab Pers Ther. 2020;35(1). https://doi.org/10.1515/dmpt-2019-0012
  17. Masukawa YM, Veríssimo GB, Vianello Richtzenhain MH, Alessandra L. Drug interactions in children with respiratory diseases in the pediatric unit of a teaching hospital in Brazil. Rev Cubana Pediatr. 2016; 88:166−81.
  18. Abideen S. Assessment of prevalence of potential drug-drug interactions in medical intensive care unit of a tertiary care hospital in india. Asian J Pharm Clin Res. 2015;8(1):125-30.
  19. Aziz G, Ahmed W, Latif MF, Saddique MA. Potential Role of Community Pharmacists in Managing Drug Interactions; a Public Perspective. Adv Pharm Ethnomed. 2014;2(1):7-9. https://doi.org/10.14737/journal.ape/2014/2.1.7.9
  20. Krupicka MI, Bratton SL, Sonnenthal K, Goldstein B. Impact of a pediatric clinical pharmacist in the pediatric intensive care unit. Crit Care Med. 2002;30(4):919-21. https://doi.org/10.1097/00003246-200204000-00035
  21. Hincapie AL, Warholak TL, Hines LE, Taylor AM, Malone DC. Impact of a drug-drug interaction intervention on pharmacy and medical students’ knowledge and attitudes: a 1-year follow-up. Res Social Adm Pharm. 2012;8(5):472-7. https://doi.org/10.1016/j.sapharm.2011.11.003
  22. Simpao AF, Ahumada LM, Desai BR, et al. Optimization of drug-drug interaction alert rules in a pediatric hospital’s electronic health record system using a visual analytics dashboard. J Am Med Inform Assoc. 2015;22(2):